Loading...
XTAI4119
Market cap330mUSD
Dec 23, Last price  
90.30TWD
1D
0.56%
1Q
1.69%
Jan 2017
59.57%
Name

SCI Pharmtech Inc

Chart & Performance

D1W1MN
XTAI:4119 chart
P/E
36.62
P/S
8.96
EPS
2.47
Div Yield, %
0.22%
Shrs. gr., 5y
0.43%
Rev. gr., 5y
-9.10%
Revenues
1.20b
+33.83%
905,738,000994,676,0001,037,853,0001,262,572,0001,292,734,0001,491,862,0001,810,501,0001,903,100,0001,301,050,0001,939,913,0002,355,747,0002,689,222,000864,217,000899,738,0001,204,159,000
Net income
295m
-4.55%
166,312,000171,244,00090,016,000194,449,000159,938,000264,839,000373,902,000416,955,000190,976,000447,237,000571,101,000360,124,00055,696,000308,780,000294,721,000
CFO
216m
-27.24%
316,958,000218,959,000249,546,000385,571,000238,571,000358,771,000663,239,000502,106,000281,651,000480,183,000791,596,000971,528,000280,278,000296,565,000215,767,000
Dividend
Jul 01, 20241.25 TWD/sh
Earnings
Mar 10, 2025

Profile

SCI Pharmtech, Inc. engages in the research and development, manufacture, and sale of active pharmaceutical ingredients (API), intermediates, and specialty chemicals. Its active pharmaceutical ingredients include Articaine HCl, Atomoxetine HCl, Bisoprolol Fumarate, Brinzolamide, Divalproex Sodium, Duloxetine HCl, Hydroxychloroquine sulfate, Loxoprofen Sodium, Methylphenidate HCl, Pentobarbital Sodium, Probucol, Propafenone HCl, Sodium Valproate, Thiopental, Valproic Acid, Adenine, Cannabidiol, and Dexmethylphenidate HCl. The company's intermediate products comprise Azetidin-3-ol hydrogenchloride, Diethyl Isobutyl Malonate, Diethyl dipropylmalonate, Diethyl ethyl(1-methylbutyl)malonate, Pyrogallolaldehyde, Benzhydrylamine, 1-Benzhydrylazetidin-3-ol, 1-(2-Hydroxyphenyl)-3-phenylpropan-1-one, N-Methyl-4-piperidinol, Ritalinic acid, d-Ritalinic acid HCl, (1R, 2S)-1 Phenyl-2-(pyrrolldin-1-yl)propan-1-ol HCl, and (1R, 2S)-1 Phenyl-2-(pyrrolldin-1-yl)propan-1-ol. Its intermediate products also consists of (S)-3-(methylmino)-1-(2-thi-enyl)propan-1-ol, (R)-3-(Methylamino)-1-phenylpropanol, (1S,4R)-1-methyl-4-(prop-1-en-2-yl)cyclohex-2-enol, Menthadienol, 5-pentylbenzene-1,3-diol Olivetol, Methyl 2,4-dihydroxy-6-pentylbenzoate, and Ethyl 2,4-dihydroxy-6-pentylbenzoate Ethyl Olivetolate. The company also provides custom manufacturing services. It sells its products in Italy, China, the United States, Germany, Taiwan, Switzerland, Spain, Japan, Netherlands, and internationally. The company was incorporated in 1987 and is based in Taoyuan City, Taiwan.
IPO date
Aug 12, 2002
Employees
Domiciled in
TW
Incorporated in
TW

Valuation

Title
TWD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
1,204,159
33.83%
899,738
4.11%
864,217
-67.86%
Cost of revenue
1,043,859
780,768
790,559
Unusual Expense (Income)
NOPBT
160,300
118,970
73,658
NOPBT Margin
13.31%
13.22%
8.52%
Operating Taxes
69,469
79,040
9,810
Tax Rate
43.34%
66.44%
13.32%
NOPAT
90,831
39,930
63,848
Net income
294,721
-4.55%
308,780
454.40%
55,696
-84.53%
Dividends
(23,846)
(39,743)
Dividend yield
0.22%
0.49%
Proceeds from repurchase of equity
957,600
BB yield
-9.03%
Debt
Debt current
196,946
112,828
1,584
Long-term debt
850,332
433,574
2,726
Deferred revenue
6,837
4,108
Other long-term liabilities
22,536
20,530
16,945
Net debt
(225,399)
171,534
(452,889)
Cash flow
Cash from operating activities
215,767
296,565
280,278
CAPEX
(1,029,360)
(1,167,584)
(774,981)
Cash from investing activities
(866,203)
(1,009,087)
(539,560)
Cash from financing activities
1,425,665
547,119
(41,516)
FCF
(1,067,018)
(1,174,634)
(368,655)
Balance
Cash
1,031,055
264,373
692,632
Long term investments
241,622
110,495
(235,433)
Excess cash
1,212,469
329,881
413,988
Stockholders' equity
2,866,363
2,350,189
2,050,384
Invested Capital
4,959,331
3,865,498
2,925,743
ROIC
2.06%
1.18%
2.61%
ROCE
2.54%
2.77%
2.14%
EV
Common stock shares outstanding
109,609
109,327
109,207
Price
96.80
11.69%
86.67
16.07%
74.67
20.01%
Market cap
10,610,151
11.98%
9,475,347
16.20%
8,154,467
19.26%
EV
10,384,752
9,646,881
7,701,578
EBITDA
305,594
209,582
137,366
EV/EBITDA
33.98
46.03
56.07
Interest
6,290
1,072
41
Interest/NOPBT
3.92%
0.90%
0.06%